NO20091413L - WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser - Google Patents

WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser

Info

Publication number
NO20091413L
NO20091413L NO20091413A NO20091413A NO20091413L NO 20091413 L NO20091413 L NO 20091413L NO 20091413 A NO20091413 A NO 20091413A NO 20091413 A NO20091413 A NO 20091413A NO 20091413 L NO20091413 L NO 20091413L
Authority
NO
Norway
Prior art keywords
wnt
diagnosis
treatment
mediated disorders
antagonists
Prior art date
Application number
NO20091413A
Other languages
English (en)
Inventor
Paul Polakis
James A Ernst
Bonnee Rubinfeld
Venita I De Almeida
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20091413L publication Critical patent/NO20091413L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Sammendrag Den foreliggende oppfinnelse tilveiebringer kimære Wnt-antagonister som omfatter en Frz-domenebestanddel avledet fra et Frizzledprotein, et utskilt Frizzled-relatert protein eller Ror-protein og en Fe-immunglobulinbestanddel, og deres anvendelse i behandlingen og den diagnostiske påvisning av cellulær Wntsignalisering og Wnt-medierte forstyrrelser, inkludert kreft.
NO20091413A 2006-09-08 2009-04-07 WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser NO20091413L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20
PCT/US2007/077845 WO2008031009A2 (en) 2006-09-08 2007-09-07 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

Publications (1)

Publication Number Publication Date
NO20091413L true NO20091413L (no) 2009-06-08

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091413A NO20091413L (no) 2006-09-08 2009-04-07 WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser

Country Status (19)

Country Link
US (5) US7947277B2 (no)
EP (1) EP2061495A2 (no)
JP (1) JP2010504081A (no)
KR (1) KR20090060334A (no)
AR (1) AR062709A1 (no)
AU (1) AU2007292242A1 (no)
BR (1) BRPI0714751A2 (no)
CA (1) CA2662041A1 (no)
CL (1) CL2007002609A1 (no)
CR (1) CR10699A (no)
IL (1) IL197240A0 (no)
MA (1) MA31135B1 (no)
MX (1) MX2009002522A (no)
NO (1) NO20091413L (no)
PE (3) PE20120806A1 (no)
RU (1) RU2009113023A (no)
SG (2) SG174101A1 (no)
TW (1) TW200819463A (no)
WO (1) WO2008031009A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513708A (ja) * 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
EP2235054A1 (en) * 2007-12-13 2010-10-06 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
CA2722485C (en) 2008-04-30 2018-02-13 F. Hoffmann-La Roche Ag Use of sfrp-3 in the assessment of heart failure
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2343080B1 (en) * 2008-09-30 2017-11-08 Kyowa Hakko Kirin Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2585098B1 (en) 2010-06-28 2014-08-27 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012054565A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
AU2011329854B2 (en) * 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP2725101B1 (en) 2011-06-21 2017-09-27 Kyowa Hakko Kirin Co., Ltd. Protein comprising truncated form of extracellular domain protein of frizzled 2, and pharmaceutical composition for treating bone diseases which comprises said protein
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
MY167232A (en) * 2012-02-20 2018-08-14 Swedish Orphan Biovitrum Ab Publ Polypeptides binding to human complement c5
CA2887711A1 (en) * 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
WO2014096163A1 (en) * 2012-12-19 2014-06-26 Affibody Ab New polypeptides
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TW201610168A (zh) 2013-12-02 2016-03-16 安可美德藥物股份有限公司 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
KR101572606B1 (ko) * 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
KR101826841B1 (ko) 2015-02-04 2018-02-08 주식회사 메드팩토 변형된 ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 이를 이용한 방법
US10913786B2 (en) * 2016-03-21 2021-02-09 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
JP2023502108A (ja) * 2019-11-18 2023-01-20 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 抗ｒｏｒ－２抗体および使用方法
EP4065599A4 (en) * 2019-11-26 2023-11-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR TREATING ILLNESSES AND CONDITIONS BY REMOVING MITOCHONDRIAL OR GENOMIC DNA FROM THE CIRCULATION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
WO1998013493A2 (en) * 1996-09-24 1998-04-02 Lxr Biotechnology, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
WO2001098354A2 (en) 2000-06-21 2001-12-27 Incyte Genomics, Inc. Human receptors
US7413873B2 (en) * 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002308557A1 (en) * 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002317105A1 (en) 2001-07-05 2003-01-21 University Of British Columbia Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20040171559A1 (en) * 2002-12-06 2004-09-02 Irving Weissman Protection of stem cells from cytotoxic agents by modulation of beta-catenin signaling pathways
US20050096263A1 (en) * 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
CA2580780A1 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
KR101549245B1 (ko) 2004-09-21 2015-09-01 로드아일랜드 하스피털, 에이 라이프스팬 파트너 Ｗｎｔ 단백질 및 암의 검출 및 치료
WO2006036175A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US8809287B2 (en) 2004-11-15 2014-08-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for altering Wnt autocrine signaling
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
AU2007292242A1 (en) 2008-03-13
SG174100A1 (en) 2011-09-29
MX2009002522A (es) 2009-06-19
US20170349639A1 (en) 2017-12-07
WO2008031009A3 (en) 2009-07-02
EP2061495A2 (en) 2009-05-27
RU2009113023A (ru) 2010-10-20
PE20081217A1 (es) 2008-09-24
US7947277B2 (en) 2011-05-24
MA31135B1 (fr) 2010-02-01
BRPI0714751A2 (pt) 2014-06-24
CL2007002609A1 (es) 2008-04-18
PE20120806A1 (es) 2012-07-25
JP2010504081A (ja) 2010-02-12
CR10699A (es) 2009-07-10
PE20120807A1 (es) 2012-07-26
IL197240A0 (en) 2011-08-01
KR20090060334A (ko) 2009-06-11
US20100266593A1 (en) 2010-10-21
US20080299136A1 (en) 2008-12-04
US20120141481A1 (en) 2012-06-07
US20110311534A1 (en) 2011-12-22
AR062709A1 (es) 2008-11-26
SG174101A1 (en) 2011-09-29
CA2662041A1 (en) 2008-03-13
WO2008031009A2 (en) 2008-03-13
TW200819463A (en) 2008-05-01

Similar Documents

Publication Publication Date Title
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
ITRM20050265A1 (it) Protesi modulare perfezionata per osteosintesi, in particolare per l'osteosintesi dell'omero.
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CR11731A (es) Composiciones y procedimientos para su preparación y uso
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
DK2049525T3 (da) N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2009026657A8 (en) Flavonoid ppar agonists
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
ATE448232T1 (de) Substituierte heterozyklen
DK2510085T3 (da) Vokenstamcelle-afledt konditioneret medium og/eller voksenstamceller til anvendelse i den terapeutiske behandling af en tumorsygdom
DK2238110T3 (da) 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application